DDInter41 DDInter458
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Cyclosporine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimetrexate
Trimetrexate {u} (Compound) binds {v} (Gene) DHFR
DHFR {u} (Gene) is downregulated by {v} (Compound) Cyclosporine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimetrexate
Trimetrexate {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Thrombocytopenia {u} (Side Effect) is caused by {v} (Compound) Cyclosporine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} (Compound) upregulates {v} (Gene) C5
C5 {u} (Gene) is upregulated by {v} (Compound) Cyclosporine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) upregulates {v} (Gene) ABCC10
ABCC10 {u} (Gene) is bound by {v} (Compound) Cyclosporine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is downregulated by {v} (Compound) Cyclosporine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} (Compound) binds {v} (Gene) HSPA5
HSPA5 {u} (Gene) is upregulated by {v} (Compound) Cyclosporine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} (Compound) palliates {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Cyclosporine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) downregulates {v} (Gene) BIRC2
BIRC2 {u} (Gene) is upregulated by {v} (Compound) Cyclosporine
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydroxyurea
Hydroxyurea {u} (Compound) treats {v} (Disease) psoriasis
psoriasis {u} (Disease) is treated by {v} (Compound) Cyclosporine
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Cyclosporine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate and Trimetrexate (Compound) binds DHFR (Gene) and DHFR (Gene) is downregulated by Cyclosporine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate and Trimetrexate (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Cyclosporine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol (Compound) upregulates C5 (Gene) and C5 (Gene) is upregulated by Cyclosporine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) upregulates ABCC10 (Gene) and ABCC10 (Gene) is bound by Cyclosporine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Cyclosporine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid (Compound) binds HSPA5 (Gene) and HSPA5 (Gene) is upregulated by Cyclosporine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid (Compound) palliates systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Cyclosporine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) downregulates BIRC2 (Gene) and BIRC2 (Gene) is upregulated by Cyclosporine (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and Hydroxyurea (Compound) treats psoriasis (Disease) and psoriasis (Disease) is treated by Cyclosporine (Compound)